#4 - Pfizer (NYSE:PFE)
Pfizer (PFE) is another one of those stocks that can find the going tough in a booming economy. Like many companies it’s only offense in the short term is that it’s not growing as fast as investors would like. They do have some questions about their pipeline of new products, and they lost exclusivity of their Viagra brand in December of 2017. All this has some analysts urging buyers to hold on this stock. However, a closer look at the analysts’ reports showed that the next largest block of analysts gave the stock a buy rating. Do they know something? Maybe, but if you’re reading this, you’re looking for stocks that should perform well in a recession. And there’s little doubt that Pfizer can play that role very well. Consumers will need, and want, their products. And since bottoming out at the beginning of the great recession in 2009, the stock has been trending upward, albeit perhaps at a slower rate than its competitors. It continues to pay a dividend. Its next dividend will be valued at $1.36 per share with a dividend yield of 3.52 percent.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
More- Current Price
- $26.50
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $31.92 (20.5% Upside)
